News
Elan Drug Technologies Announces Completion of Enrolment in Phase 3
Elan Drug Technologies, a business unit of Elan Corporation, plc announced that Zogenix Inc, its licensee, has completed enrolment in its open-label Phase 3 study (Study 802) of ZX002, a novel, oral, single-entity, controlled-release formulation of hydrocodone. ZX002, which...
News
Aurobindo Pharma receives FDA tentative approval for Duloxetine Hydrochloride Delayed Release Capsules
Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the US FDA to manufacture and market Duloxetine Hydrochloride Delayed-Release Capsules 20mg (base), 30mg (base) and 60mg (base). Duloxetine Hydrochloride Delayed-Release...
News
Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
Amgen announced that it will present data from several key Nplate(R) (romiplostim) studies at the 52nd Annual Meeting and Exposition of the ASH, Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with...
News
Merck to Acquire SmartCells, Inc
Merck & Co., Inc., and SmartCells, Inc., announced that they have entered into a definitive agreement under which Merck will acquire SmartCells, a private company developing a glucose responsive insulin formulation for the treatment of diabetes mellitus. ...
News
Cold Chain Smart Solutions Conference
While cold chain management is becoming an evermore important part of a pharmaceutical firm’s business capability, it is also big business from the logistics point of view. Pharma Supply Chain is a complex interplay of product,...
News
Ranbaxy Launches Donepezil 5MG and 10MG Tablets
Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received final approval from the U.S. FDA to manufacture and market Donepezil Hydrochloride Tablets 5 mg and 10 mg with 180 day market...
News
Quintiles and London Genetics Alliance T0 Enchance Drug Discovery and Development
Quintiles, the world’s leading bio pharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the bio pharmaceutical industry innovative pharmacogenetics solutions to advance...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read